- Trials with a EudraCT protocol (41)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
41 result(s) found for: Immune receptors.
Displaying page 1 of 3.
EudraCT Number: 2011-002082-38 | Sponsor Protocol Number: RG_11-123 | Start Date*: 2012-04-16 |
Sponsor Name:University of Birmingham | ||
Full Title: A study of the effects of Simvastatin on neutrophil function in elderly subjects | ||
Medical condition: We are investigating the effects of Simvastatin 80mg on neutrophil function (using in vitro studies of neutrophil function), in healthy elderly subjects as there is evidence to suggest that Simvast... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003998-17 | Sponsor Protocol Number: ONCOGHdC2015-01 | Start Date*: 2017-02-16 |
Sponsor Name:Grand Hôpital de Charleroi | ||
Full Title: A phase Ib/II study of Durvalumab (MEDI4736) combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE) | ||
Medical condition: patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001039-29 | Sponsor Protocol Number: ESCAPE | Start Date*: 2020-04-01 | |||||||||||
Sponsor Name:HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS | |||||||||||||
Full Title: EFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH: THE ESCAPE CLINICAL TRIAL | |||||||||||||
Medical condition: Organ dysfunction by the novel SARS-Cov-2 virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003343-29 | Sponsor Protocol Number: RG_12-179 | Start Date*: 2013-01-18 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Simvastatin as adjuvant therapy to correct neutrophil dysfunction in older pneumonia patients - a randomised double blind placebo controlled trial | |||||||||||||
Medical condition: Acute episodes of Pneumonia and sepsis in older adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002077-21 | Sponsor Protocol Number: ICR-CTSU/2017/10065 | Start Date*: 2019-04-18 | |||||||||||
Sponsor Name:The Institute of Cancer Research | |||||||||||||
Full Title: PHOENIX Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemoth... | |||||||||||||
Medical condition: Triple Negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000911-25 | Sponsor Protocol Number: BST-LT-01 | Start Date*: 2019-02-12 | |||||||||||
Sponsor Name:Banc de Sang i Teixits | |||||||||||||
Full Title: A prospective multicenter open, not controlled phase Ib-II clinical trial to assess the safety and immunologic efficacy of virus-specific T lymphocytes from the best donor in receptors of hematopoi... | |||||||||||||
Medical condition: CMV viral infection in an immunocompromised host | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006644-19 | Sponsor Protocol Number: CRISTAL | Start Date*: 2009-01-29 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA | |||||||||||||
Full Title: Evaluation of inflammatory immune parameters predicting cardiovascular risk in HIV-1-infected antiretroviral therapy naive patients treated with atazanavir/ritonavir versus lopinavir/ritonavir base... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001364-29 | Sponsor Protocol Number: AdiQure/COVID-19 | Start Date*: 2020-04-20 | |||||||||||||||||||||
Sponsor Name:Red Andaluza de Diseño y Traslación de Terapias Avanzadas-Fundación Progreso y Salud | |||||||||||||||||||||||
Full Title: Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia | |||||||||||||||||||||||
Medical condition: Severe COVID-19 pneumonia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001514-34 | Sponsor Protocol Number: ILNK15-01 | Start Date*: 2012-04-03 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Infusion of IL-15 activated NK cells after allogeneic stem cell transplantation in children transplanted for relapsed/refractory leukemia: a feasibility study | |||||||||||||
Medical condition: Children with high-risk and recurrent acute leukemia are eligible for allogeneic hematopoietic stem cell transplantation (HSCT). However, leukemia relapse and viral infections after HSCT remain mai... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000538-31 | Sponsor Protocol Number: Neuroimpa2015 | Start Date*: 2015-06-01 | |||||||||||
Sponsor Name:Charité University medicine Berlin | |||||||||||||
Full Title: NEUORIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the knee joint | |||||||||||||
Medical condition: chronic arthritis of the knee joint effusion as part of spondyloarthritis (Assessments in SpondyloArthritis international Society, ASAS criteria), Rheumatoid Arthritis, RA (according to American Co... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000966-23 | Sponsor Protocol Number: BCG_influenza | Start Date*: 2014-05-30 | |||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | |||||||||||||
Full Title: The effects of BCG-vaccination on the immune response induced by influenza-vaccination in healthy volunteers A pilot proof-of-principle study | |||||||||||||
Medical condition: Influenza virus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005520-42 | Sponsor Protocol Number: BCG-LPS | Start Date*: 2014-04-28 | |||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | |||||||||||||
Full Title: The effects of BCG-vaccination on the innate immune response and immunoparalysis in healthy volunteers | |||||||||||||
Medical condition: sepsis induced immunoparalysis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001597-33 | Sponsor Protocol Number: 20081203 | Start Date*: 2009-06-18 | |||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||
Full Title: Development of chronic disease in newly diagnosed Idiopathic Thrombocytopenic Purpura of Childhood. A randomized controlled study on the influence of treatment with intravenous gammaglobulin on the... | |||||||||||||
Medical condition: Acute Idiopathic Thrombocytopenic Purpura (ITP) in children | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001857-14 | Sponsor Protocol Number: UC-0101/1709 | Start Date*: 2018-04-18 |
Sponsor Name:UNICANCER | ||
Full Title: A phase I/II basket trial evaluating a combination of Metronomic Oral Vinorelbine plus anti-PD-L1/anti-CTLA4 ImmunothErapy in patients with advanced solid tumours. | ||
Medical condition: Patients with Histologically confirmed locally advanced or metastatic solid tumours, resistant to conventional therapies, and candidate to experimental therapy by local clinical board, from the fol... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003645-25 | Sponsor Protocol Number: 20110261 | Start Date*: 2016-03-21 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects with Advanced Non Central Nervous SystemTumors Th... | |||||||||||||
Medical condition: Non-Central Nervous System (CNS) Tumors | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Completed) SE (Prematurely Ended) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000097-35 | Sponsor Protocol Number: CCFZ533X2204 | Start Date*: 2015-09-02 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily evaluate the safety, tolerability, pharmacokinetics and efficacy of CFZ533 in patients with moder... | |||||||||||||
Medical condition: Acquired myasthenia gravis (MG) is an autoimmune disease that leads to fluctuating muscle weakness and fatigue. In the most common cases, muscle weakness is caused by circulating antibodies that bi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000172-38 | Sponsor Protocol Number: NP137-CT-02 | Start Date*: 2020-09-04 | |||||||||||||||||||||||||||||||
Sponsor Name:NETRIS PHARMA | |||||||||||||||||||||||||||||||||
Full Title: A randomised, multicentre, open label, Phase I/II study to evaluate the safety (Phase I - safety run in), clinical and biological activity (Phase II) of a humanized monoclonal antibody targeting Ne... | |||||||||||||||||||||||||||||||||
Medical condition: Locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002488-91 | Sponsor Protocol Number: MO39874 | Start Date*: 2019-11-04 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: AN OPEN-LABEL, PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) PLUS NAB-PACLITAXEL IN THE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC PD-L1-POSITIVE TRIPLE-NEGATI... | |||||||||||||
Medical condition: Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) SI (Completed) FR (Completed) HU (Completed) SK (Prematurely Ended) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005762-34 | Sponsor Protocol Number: MGCDB001 | Start Date*: 2021-07-15 | |||||||||||
Sponsor Name:Medical University of Lublin | |||||||||||||
Full Title: A phase 2 clinical trial assessing the efficacy and safety of adding cladribine for treatment modifying course of seropositive myasthenia gravis | |||||||||||||
Medical condition: Myasthenia gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003406-47 | Sponsor Protocol Number: FS118-21201 | Start Date*: 2022-03-08 | |||||||||||
Sponsor Name:F-star Therapeutics Limited | |||||||||||||
Full Title: A Phase 2 Open-Label Basket Study of FS118, a LAG-3/PD-L1 Bispecific Antibody, in Subjects with Advanced and Early-Stage Malignancies | |||||||||||||
Medical condition: Advanced and early-stage malignancies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
